Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies-Reference-Cited by-同舟云学术

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

Published:2023-04 Issue:10383 Volume:401 Page:1159-1171
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Sandborn William J,Vermeire Séverine,Peyrin-Biroulet Laurent,Dubinsky Marla C,Panes Julian,Yarur Andres,Ritter Timothy,Baert Filip,Schreiber Stefan,Sloan Sheldon,Cataldi Fabio,Shan Kevin,Rabbat Christopher J,Chiorean Michael,Wolf Douglas C,Sands Bruce E,D'Haens Geert,Danese Silvio,Goetsch Martina,Feagan Brian G

Funder

Arrien Pharmaceuticals

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Ulcerative colitis;Ungaro;Lancet,2017

2. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD;Turner;Gastroenterology,2021

3. AGA technical review on the management of moderate to severe ulcerative colitis;Singh;Gastroenterology,2020

4. JAK inhibitors safety in ulcerative colitis: practical implications;Agrawal;J Crohn's Colitis,2020

5. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation;Hla;Neurology,2011

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects;European Journal of Medicinal Chemistry;2024-10

2. Dysregulation of sphingolipid metabolism in liver fibrosis;Metabolism and Target Organ Damage;2024-09-14

3. Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis;Expert Opinion on Drug Metabolism & Toxicology;2024-09-12

5. Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2024-09-09